Journal of Gastroenterology

, Volume 40, Issue 8, pp 833–835

Safety and efficacy of therapy with botulinum toxin in obesity: a pilot study

Authors

  • Giovanni Albani
    • Divisions of Nutrition and Gastrointestinal RehabilitationIRCCS Istituto Auxologico Italiano
  • Maria Letizia Petroni
    • Divisions of Nutrition and Gastrointestinal RehabilitationIRCCS Istituto Auxologico Italiano
  • Alessandro Mauro
    • Divisions of Nutrition and Gastrointestinal RehabilitationIRCCS Istituto Auxologico Italiano
  • Antonio Liuzzi
    • Divisions of Nutrition and Gastrointestinal RehabilitationIRCCS Istituto Auxologico Italiano
  • Giovanni Lezzi
    • Divisions of Nutrition and Gastrointestinal RehabilitationIRCCS Istituto Auxologico Italiano
  • Barbara Verti
    • Divisions of Nutrition and Gastrointestinal RehabilitationIRCCS Istituto Auxologico Italiano
  • Paolo Marzullo
    • Divisions of Nutrition and Gastrointestinal RehabilitationIRCCS Istituto Auxologico Italiano
  • Laila Cattani
    • Divisions of Nutrition and Gastrointestinal RehabilitationIRCCS Istituto Auxologico Italiano
Rapid communication

DOI: 10.1007/s00535-005-1669-x

Cite this article as:
Albani, G., Petroni, M., Mauro, A. et al. J Gastroenterol (2005) 40: 833. doi:10.1007/s00535-005-1669-x

Abstract

Background

Botulin toxin (BTX) has been proposed as a potential obesity treatment.

Methods

In a pilot study, the short-term efficacy and safety of BTX was assessed in eight subjects (four men, four women; median age, 46 years; range, 35–57 years) with severe obesity (median body mass index [BMI], 47.1 kg/m2; range 38.2–56.7 kg/m2) and multiple dietary treatment failures. In a single endoscopic session, 500 UI of BTX-A was injected in the gastric antral region.

Results

No clinically significant side effects were observed. In all patients, despite their not being on a specific diet, a reduction of body weight was observed at 1 month (median baseline weight, 124.4 kg vs 121.8 kg at 1 month; P < 0.05). Two treatment-unrelated dropouts were observed. At 4 months, three of the six patients had a further weight loss. The treatment effect was apparently independent of changes in hunger or satiety, or of changes in fasting and postprandial plasma ghrelin and serum leptin, thus suggesting a different pharmacological mechanism.

Conclusions

BTX-A treatment appears to be safe and well tolerated by obese patients, while its short-term efficacy varied widely.

Key words

obesityghrelinleptinendoscopybotulinum toxin

Copyright information

© Springer-Verlag Tokyo 2005